Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global breast cancer core needle biopsy market size was estimated at USD 869.8 million in 2024 and is expected to grow at a CAGR of 4.6% from 2025 to 2030. The market is experiencing significant growth, fueled by the rising incidence of breast cancer and advancements in imaging and biopsy technologies. According to the International Agency for Research on Cancer, in 2022, 2.29 million cases of breast tumor were reported worldwide, which are likely to grow to 2.69 million by 2030. Core needle biopsies provide notable benefits compared to traditional surgical methods, including being minimally invasive, promoting quick recovery, and offering cost efficiency. As awareness of early detection continues to expand globally, the demand for core needle biopsies is anticipated to increase further due to their vital role in early diagnosis and improved patient outcomes.

In 2021, the World Health Organization (WHO) launched the Global Breast Cancer Initiative (GBCI) Framework, a comprehensive strategy aimed at addressing the growing burden of mammary tumors worldwide. This initiative outlines a clear plan with the ambitious target of saving 2.5 million lives by 2040. Mammary tumor, which affects over 2.3 million individuals annually, is the most common tumors among adults and the leading cause of tumor-related deaths among women in 95% of countries.

The effects of mammary tumors extend beyond patients, often leaving lasting impacts on families and communities. A study conducted by the International Agency for Research on Cancer (IARC) in 2020 highlighted that approximately 1.0 million children were orphaned due to tumors, with 25% of these cases linked to mammary tumors.

In resource-limited settings, advancements in diagnostic methods, such as mammography and biopsy, are facilitating a shift from traditional mastectomy to less invasive procedures like lumpectomy. Innovative approaches are also being explored, such as a reusable, cost-effective, and sterile core biopsy device developed at Johns Hopkins University, which received the Lemelson-MIT prize. Core needle biopsy, widely used to analyze non-palpable tumors, achieves a high accuracy rate of about 90% in tissue sampling.

The combination of molecular analysis with core needle biopsy techniques allows for detailed profiling of genetic and protein alterations in tumors, enabling personalized treatment plans and monitoring therapy responses. Devices like PrecisionCore, which integrate real-time ultrasound guidance with advanced imaging, enhance the precision of tissue sample extraction. These advancements show significant potential to improve mammary tumor diagnosis and treatment outcomes, particularly in low-resource environments.

Technology insights

The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages. In addition, the rise in product launches and regulatory approvals is anticipated to further boost segment growth. For instance, in April 2021, Mammotome introduced the HydroMARK breast biopsy site marker, designed to enhance long-term ultrasound visibility. Similarly, in August 2022, TransMed7, LLC unveiled its SpeedBird mammary biopsy device, which offers improved ease in performing image-guided biopsies. Furthermore, in June 2024, a group of doctors at Soochow University developed a contrast-enhanced ultrasound-based model which enables detection of axillary lymph node metastasis in mammary cancer patients. These advancements in the industry are expected to contribute significantly to the segment's growth.

CT-based breast biopsy is anticipated to grow at a CAGR of 3.8% in the coming years. The segment growth is driven by ongoing technological advancements in CT breast biopsy and improved accessibility to this technology. Additionally, increased research and development efforts are expected to further support the segment's growth. Techniques such as FDG PET/CT and FES PET/CT have also demonstrated their potential to enhance the diagnosis and treatment of metastatic mammary tumors, contributing to the segment's expansion.

End-use Insights

The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024. The increasing number of patient visits to hospitals, along with the rising adoption of advanced instruments and equipment in healthcare facilities, is expected to create a supportive environment for the segment's growth. In addition, the segment is anticipated to experience the fastest CAGR during the forecast period, driven by the rapid expansion in the installation of biopsy instruments. For instance, in July 2024, Sir HN Reliance Foundation Hospital installed the first MR fusion biopsy instrument, which uses artificial intelligence to detect tumorous growth. These developments are expected to further boost the segment's growth prospects.

The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry. The growing investments in academic institutions to support research activities are expected to drive the segment's growth. For example, in October 2023, the Bren Simon Comprehensive Cancer Center and Indiana University Melvin were awarded USD 2.2 million in funding for research on metastatic mammary tumor. Such financial support is likely to accelerate innovation and advancements in the field, further contributing to the segment's expansion.

Regional Insights

North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024. The strong market leadership is attributed to its advanced healthcare systems, robust research capabilities, and concerted efforts to increase patient awareness. These factors collectively enhance early mammary tumor detection and improve management outcomes. Prominent medical institutions and diagnostic centers in the U.S. and Canada consistently advocate for regular screenings.

U.S. Breast Cancer Core Needle Biopsy Market Trends

The breast cancer core needle biopsy industry in the U.S. is estimated to grow progressively during the forecast period. The U.S. has a well-established healthcare system with access to cutting-edge medical technology and highly skilled healthcare professionals. This enables the adoption of advanced diagnostic tools, such as core needle biopsies, which are minimally invasive and highly effective in diagnosing mammary tumors

Europe Breast Cancer Core Needle Biopsy Market Trends

The Europe breast cancer core needle biopsy industry is likely to emerge as a lucrative region. There is a strong emphasis on early detection and screening for mammary tumors in public health campaigns and guidelines, such as those from the European Commission, which promote regular screening and the use of advanced diagnostic methods. This has increased patient awareness and demand for early-stage diagnostics

The breast cancer core needle biopsy market in the UK is projected to grow during the forecast period. The UK has a high incidence of breast tumors, driving demand for more diagnostic procedures, including biopsies. The growing number of mammary tumors cases is leading to an increased need for early-stage diagnostic methods like core needle biopsy to ensure better treatment outcomes.

France breast cancer core needle biopsy market is expected to show steady growth over the forecast period. France has national screening programs aimed at early detection of mammary tumors, such as The organized breast cancer screening program which invites women aged 50 to 74 for regular mammograms. This program has contributed to higher awareness and early-stage detection, driving the demand for biopsy procedures like core needle biopsies.

The breast cancer core needle biopsy market in Germany is projected to expand during the forecast period. There is a growing preference for minimally invasive diagnostic methods in Germany, especially in oncology. Core needle biopsy is favored due to its ability to provide accurate results with minimal discomfort and recovery time compared to traditional surgical biopsies. This has driven its adoption for diagnosing mammary tumors.

Asia Pacific Breast Cancer Core Needle Biopsy Market Trends

The Asia Pacific breast cancer core needle biopsy industry is expected to experience the highest growth rate of 5.2% CAGR during the forecast period. The incidence of mammary tumors is on the rise across several countries, such as China, India, Japan, and South Korea. This is driving the demand for early diagnostic methods like core needle biopsy, as these countries are focusing on improving tumor detection and treatment outcomes.

The breast cancer core needle biopsy market in China is projected to expand throughout the forecast period. China has been making significant investments in healthcare infrastructure, including modern hospitals and diagnostic centers equipped with advanced medical technologies. With improvements in diagnostic equipment, such as mammography, ultrasound, and MRI, core needle biopsy is becoming more accessible to patients, further supporting market growth.

Japan breast cancer core needle biopsy market is anticipated to grow during the forecast period, driven by the presence of advanced healthcare infrastructure, high cancer awareness, and technological innovations in diagnostics.

Latin America Breast Cancer Core Needle Biopsy Market Trends

The breast cancer core needle biopsy industry in the Latin America is likely to show significant growth over the forecast period. Breast tumor is one of the most common cancers among women in Latin America. Countries such as Brazil and Argentina have seen an increase in the number of breast cancer cases in the past few years, which is likely to drive demand for better diagnostic methods.

Brazil breast cancer core needle biopsy market is anticipated to grow during the forecast period. The Brazilian government has made efforts to improve breast cancer diagnosis and treatment through national screening programs. Initiatives like the Program for the Early Detection of Breast Cancer aim to provide mammography services to women over 50 and encourage earlier detection of the disease.

Middle East And Africa Breast Cancer Core Needle Biopsy Market Trends

The breast cancer core needle biopsy market in the Middle East and Africa is anticipated to grow at a steady rate over the forecast period. The regional market is growing due to the increasing prevalence of breast cancer, one of the most common cancers among women in the region. Improved awareness campaigns and early detection initiatives have fueled the need for accurate diagnostic tools in the region.

Saudi Arabia breast cancer core needle biopsy market is expected to show substantial growth in the coming years. The Saudi government has implemented a range of initiatives aimed at improving cancer detection and treatment, including cancer. The country’s Vision 2030 healthcare reforms aim to enhance the overall quality and accessibility of healthcare services, with a particular focus on cancer care.

Key Breast Cancer Core Needle Biopsy Company Insights

The breast cancer core needle biopsy industry is witnessing significant growth due to the rising demand for effective diagnostic procedures in breast cancer treatment. This creates substantial opportunities for key market players to expand their presence. To capitalize on the growing demand, many companies are adopting strategic approaches such as mergers, acquisitions, and collaborations to strengthen their market position and offer advanced products and services. For instance, in November 2024, Mammotome announced the launch of Mammotome AutoCore which is a spring loaded biopsy device which enables easy specimen collection. With this launch, the company is focusing on increasing their market presence and customer base across physicians and clinicians.

Recent Developments

• In November 2024, Mammotome launched Mammotome AutoCore which is a core biopsy device for breast tissue examinations. The system provides notable benefits compared to traditional core needle devices, streamlining procedures for healthcare providers while enhancing the overall patient experience. By reducing the time required for biopsies, it allows physicians to perform procedures more efficiently, ultimately benefiting both clinical outcomes and patient comfort.

• In January 2023, NovaScan initiated a human gastrointestinal clinical trial for its nsCanary device at the Texas International Endoscopy Center. The nsCanary device is designed to assist clinicians in detecting cancer in tissue samples obtained through various biopsy methods, including Endoscopic Ultrasound (EUS), fine needle biopsy, biopsy forceps, and polypectomy snare. The aim of this innovative device is to improve cancer diagnostics and support more informed treatment decisions, particularly in gastrointestinal conditions. This initiative reflects the growing emphasis on enhancing diagnostic accuracy through advanced technology, which is crucial for early cancer detection and effective treatment planning.

• In November 2024, a team of researchers at the Center for Global Women's Health Technologies was granted USD 10.4 million for breast cancer research. The aim of the research project is to eliminate mortality and improve overall access to treatment and diagnosis of breast cancer

Breast Cancer Core Needle Biopsy Market Report Scope

Global Breast Cancer Core Needle Biopsy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels, and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global breast cancer core needle biopsy market report based on technology, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • MRI-based Breast Biopsy

  • Ultrasound-based Breast Biopsy

  • Mammography-based (Stereotactic) Breast Biopsy

  • CT-based Breast Biopsy

  • Other Image Based Breast Biopsy

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Diagnostic Laboratories

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait